

# Holding the balance; the equilibrium between ERα-activation, epigenetic alterations and chromatin integrity Flach, K.D.

Citation

Flach, K. D. (2018, September 25). Holding the balance; the equilibrium between  $ER\alpha$ activation, epigenetic alterations and chromatin integrity. Retrieved from https://hdl.handle.net/1887/66110

Version:	Not Applicable (or Unknown)
License:	<u>Licence agreement concerning inclusion of doctoral thesis in the</u> <u>Institutional Repository of the University of Leiden</u>
Downloaded from:	https://hdl.handle.net/1887/66110

Note: To cite this publication please use the final published version (if applicable).

Cover Page



### Universiteit Leiden



The handle <u>http://hdl.handle.net/1887/66110</u> holds various files of this Leiden University dissertation.

**Author**: Flach, K.D. **Title**: Holding the balance; the equilibrium between ERα-activation, epigenetic alterations and chromatin integrity **Issue Date**: 2018-09-25

## Holding the balance; the equilibrium between ERα-activation, epigenetic alterations and chromatin integrity

Thesis Outline

#### **General introduction**

In this thesis we reflect on the effects differential DNA binding of the estrogen receptor  $\alpha$  (ER $\alpha$ ) can have on the behavior of breast cancer and which factors can contribute to this. Approximately 70% of all breast tumors are derived from the inner lining of cells in the mammary ducts (also known as luminal tumors) and their proliferation is dependent on the activity of (ER $\alpha$ ). During the development and homeostasis of the female reproductive organs ER $\alpha$  plays a key role. In ER $\alpha$ -positive breast tumors however, ER $\alpha$  has a causative role in carcinogenesis (1). ER $\alpha$  can be activated by its natural ligand estradiol (2), a steroidal estrogen, which can induce the formation of an activated ER $\alpha$ -dimer. After a conformational change (3), this dimer "opens up" the co-activator-binding pocket (4) resulting in the recruitment of essential co-factors (5) leading to the assembly of the ER $\alpha$ -transcriptional complex.

One of the mainstay endocrine treatment options for ER $\alpha$ -positive breast cancer patients is tamoxifen (6-8), which is an ER $\alpha$  antagonist and competitively inhibits the interaction of ER $\alpha$  and estrogen, thereby repressing ER $\alpha$  activity (9-11). Alternatively aromatase inhibitors can be used to block the synthesis of estrogen, rendering ER $\alpha$  inactive. Despite these therapeutic options, still a significant proportion of patients develop a recurrence. Although cross-resistance between the different therapeutic options does occur, a proportion of patients that relapse on one type of therapy can still benefit from a different treatment modality. This illustrates the existence of multiple resistance mechanisms which can be treatment selective. A better understanding of ER $\alpha$ -biology and the development of drug resistance, cannot only provide us with novel mechanistic insights, but could also lead the way to the discovery of novel biomarkers and potential drug targets, which can further increase patient survival.

#### Thesis outline

**Chapter 1** provides a general overview of ER $\alpha$ -biology and more specifically the mechanistic insights the genome-wide interrogation of ER $\alpha$ -chromatin binding has brought us. Furthermore we discuss where future developments might take us.

**Chapter 2** describes a well-known mechanism of tamoxifenresistance; the PKA-induced phosphorylation of ER $\alpha$  at Serine residue 305 (ER $\alpha$ S305-P). We report on the implications this phosphorylation has on the binding repertoire of ER $\alpha$  and describe the discovery of an altered gene expression profile capable of predicting the outcome of patients treated with tamoxifen.

In **Chapter 3** we provide experimental evidence for a previously unknown ER $\alpha$ -phosphorylation (T594P) and demonstrate how this greatly diminished ER $\alpha$ 's binding capacity. Additionally we show that by stabilizing this phosphorylation by administering fusicoccin, ER $\alpha$ -mediated gene transcription was reduced and tumor cell growth was inhibited.

In **Chapter 4** we report on the fact that ER $\alpha$ -function can also be altered by other nuclear receptors and demonstrate that LRH-1 knockdown led to an altered gene expression profile. Additionally we revealed that there is a large overlap between chromatin binding sites of LRH-1 and ER $\alpha$ , and that at these overlapping regions a synergistic stimulation is present.

In **Chapter 5** we computationally refined a 111-gene classifier towards a single gene classifier, revealing that FEN1 levels are predictive of outcome in ER $\alpha$ -positive patients treated with tamoxifen. We describe our findings on the complex regulatory interplay between FEN1 and ER $\alpha$ , and postulate three manners by which FEN1 may modulate ER $\alpha$  activity. Additionally we performed a drug screen which led to the discovery of a FEN1-specific and potent inhibitor. We demonstrate a clear sensitivity of ER $\alpha$ -positive breast cancer cell lines to this inhibitor when compared to ER $\alpha$ -negative cell lines, and an even greater sensitivity of tamoxifen-resistant cell lines. The latter suggesting FEN1 inhibition might be a useful novel therapeutic option in the case of tamoxifen resistant breast.

**Chapter 6** contains our findings on the phosphorylation of essential ER $\alpha$ -cofactor SRC3 (SRC3-pS543). This phosphorylation leads to an altered deposition of SRC3 at the chromatin, making it very likely to also alter the gene expression of breast cancer and thereby its phenotype. Furthermore a SRC3-pS543 phospho-specific antibody was capable of identifying patients

#### Thesis outline

with a functional ER $\alpha$  pathway, rendering it a promising novel biomarker for tamoxifen efficacy.

In **Chapter 7** I discuss what the implications of our findings are with regards to a better understanding of  $ER\alpha$ -biology and describe the new questions this may invoke. Additionally I discuss how the novel biomarkers described in this thesis could aid in patient stratification and what type of research is still required to successfully implement such a biomarker. With regards to the potential novel drug targets we identified, I describe what the current clinical value of these drug targets would be and what type of evidence still lacks.

#### References

1. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer. 2003;10(2):193-202.

2. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006;58(4):773-81.

3. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci U S A. 1999;96(7):3999-4004.

4. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95(7):927-37.

5. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol. 1997;9(2):222-32.

6. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003;12(6):362-7.

7. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351(9114):1451-67.

8. Gradishar WJ. Tamoxifen--what next? Oncologist. 2004;9(4):378-84.

9. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev. 1990;11(4):578-610.

10. Katzenellenbogen BS, Miller MA, Mullick A, Sheen YY. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res Treat. 1985;5(3):231-43.

11. Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, et al. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology. 2009;77 Suppl 1:23-37.